血管運動症状市場レポート：2030年までの動向、予測、競合分析

血管運動症状の動向と予測

世界の血管運動症状市場は、2024年から2030年にかけてCAGR 5.8％で成長すると予測されます。この市場の主な促進要因は、座りっぱなしのライフスタイル、遺伝、ホルモンの変動、食生活の乱れによる血管運動器症状の頻度の上昇、研究開発に資金を提供する企業や潜在的な臨床試験参入企業の増加です。血管運動症状の世界市場の将来は、病院や診療所、専門センター市場における機会によって有望視されています。

血管運動症状市場の洞察

Lucintelの予測では、血管運動症状に対する効果的な治療のため、予測期間中、併用療法がより大きなセグメントであり続けると思われます。

この市場の中では、血管運動症状の治療に関する専門知識が豊富な専門センターが引き続き大きなセグメントとなると思われます。

北米は更年期障害の有病率が高いため、予測期間中も最大の地域であり続けるでしょう。

よくある質問

Q1.市場の成長予測は？

A1.世界の血管運動症状市場は、2024年から2030年にかけてCAGR 5.8％で成長すると予想されています。

Q2.市場の成長に影響を与える主な促進要因は？

A2.この市場の主な促進要因は、座りがちなライフスタイル、遺伝、ホルモンの変動、食生活の乱れによる血管運動症状の頻度の上昇、研究開発に資金を提供する企業や潜在的な臨床試験参入企業の増加です。

Q3.市場の主要セグメントは？

A3.血管運動症状市場の将来は、病院・診療所および専門センター市場での機会により有望視されています。

Q4.市場の主要企業は？

A4.血管運動症状の主要企業は以下の通りです。

• Teva Pharmaceuticals
• Merck
• Mithra Pharmaceuticals
• Procter And Gamble
• Therapeuticsmd
• Emcure Pharmaceuticals
• Eli Lily And Company
• Novartis
• Novo Nordisk
• Pfizer

Q5.今後、最大となる市場セグメントは？

A5.Lucintelは、血管運動症状に対する効果的な治療のため、予測期間中、併用療法がより大きなセグメントであり続けると予測しています。

Q6.市場において、今後5年間に最大になると予想される地域は？

A6.北米では更年期障害の有病率が高いため、予測期間中も北米が最大地域であり続けます。

Q7.レポートのカスタマイズは可能？

A7.はい、Lucintelは追加費用なしで10％のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の血管運動症状市場：市場力学

• イントロダクション、背景、分類
• サプライチェーン
• 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

• マクロ経済動向（2018～2023年）と予測（2024～2030年）
• 世界の血管運動症状市場の動向（2018-2023）と予測（2024-2030）
• 世界の血管運動症状市場：治療法別
  • エストロゲン
  • プロゲステロン
  • 組み合わせ
  • 市販ホルモン
  • 抗うつ薬
  • その他
• 世界の血管運動症状市場：流通チャネル別
  • 病院薬局
  • 小売薬局
  • ドラッグストア
• 世界の血管運動症状市場：最終用途別
  • 病院と診療所
  • 専門センター
  • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

• 地域別の世界の血管運動症状市場
• 北米の血管運動症状市場
• 欧州の血管運動症状市場
• アジア太平洋の血管運動症状市場
• その他地域の血管運動症状市場

第5章 競合の分析

• 製品ポートフォリオ分析
• 運用上の統合
• ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

• 成長機会分析
  • 治療法別の世界の血管運動症状市場の成長機会
  • 流通チャネル別の世界の血管運動症状市場の成長機会
  • 最終用途別の世界の血管運動症状市場の成長機会
  • 地域別の世界の血管運動症状市場の成長機会
• 世界の血管運動症状市場の新たな動向
• 戦略的分析
  • 新製品の開発
  • 世界の血管運動症状市場の能力拡大
  • 世界の血管運動症状市場における合併、買収、合弁事業
  • 認証とライセンシング

第7章 有力企業の企業プロファイル

• Teva Pharmaceuticals
• Merck
• Mithra Pharmaceuticals
• Procter and Gamble
• TherapeuticsMD
• Emcure Pharmaceuticals
• Eli Lily and Company
• Novartis
• Novo Nordisk
• Pfizer

Vasomotor Symptoms Trends and Forecast

The future of the global vasomotor symptoms market looks promising with opportunities in the hospitals and clinics and specialty centers markets. The global vasomotor symptoms market is expected to grow with a CAGR of 5.8% from 2024 to 2030. The major drivers for this market are rising frequency of vasomotor symptoms as a result of sedentary lifestyle, heredity, hormonal fluctuations, and poor eating patterns and increase in the quantity of businesses funding R&D and potential clinical trial participants.

A more than 150-page report is developed to help in your business decisions.

Vasomotor Symptoms by Segment

The study includes a forecast for the global vasomotor symptoms by therapy type, distribution channel, end use, and region.

Vasomotor Symptoms Market by Therapy Type [Shipment Analysis by Value from 2018 to 2030]:

• Estrogen
• Progesterone
• Combination
• OTC Hormone
• Anti-Depressants
• Others

Vasomotor Symptoms Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

• Hospital Pharmacy
• Retail Pharmacy
• Drug Stores

Vasomotor Symptoms Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

• Hospitals And Clinics
• Specialty Centers
• Others

Vasomotor Symptoms Market by Region [Shipment Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Vasomotor Symptoms Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies vasomotor symptoms companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the vasomotor symptoms companies profiled in this report include-

• Teva Pharmaceuticals
• Merck
• Mithra Pharmaceuticals
• Procter And Gamble
• Therapeuticsmd
• Emcure Pharmaceuticals
• Eli Lily And Company
• Novartis
• Novo Nordisk
• Pfizer

Vasomotor Symptoms Market Insights

Lucintel forecasts that combination will remain the larger segment over the forecast period due to effective treatment for vasomotor symptoms.

Within this market, specialty centers will remain the larger segment due to more expertise in treating vasomotor symptoms.

North America will remain the largest region over the forecast period due to high prevalence of menopause in north america.

Features of the Global Vasomotor Symptoms Market

Market Size Estimates: Vasomotor symptoms market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Vasomotor symptoms market size by therapy type, distribution channel, end use, and region in terms of value ($B).

Regional Analysis: Vasomotor symptoms market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different therapy type, distribution channel, end use, and regions for the vasomotor symptoms market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the vasomotor symptoms market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for vasomotor symptoms market?

Answer: The global vasomotor symptoms market is expected to grow with a CAGR of 5.8% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the vasomotor symptoms market?

Answer: The major drivers for this market are rising frequency of vasomotor symptoms as a result of sedentary lifestyle, heredity, hormonal fluctuations, and poor eating patterns and increase in the quantity of businesses funding R&D and potential clinical trial participants.

Q3. What are the major segments for vasomotor symptoms market?

Answer: The future of the vasomotor symptoms market looks promising with opportunities in the hospitals and clinics and specialty centers markets.

Q4. Who are the key vasomotor symptoms market companies?

Answer: Some of the key vasomotor symptoms companies are as follows.

• Teva Pharmaceuticals
• Merck
• Mithra Pharmaceuticals
• Procter And Gamble
• Therapeuticsmd
• Emcure Pharmaceuticals
• Eli Lily And Company
• Novartis
• Novo Nordisk
• Pfizer

Q5. Which vasomotor symptoms market segment will be the largest in future?

Answer: Lucintel forecasts that combination will remain the larger segment over the forecast period due to effective treatment for vasomotor symptoms.

Q6. In vasomotor symptoms market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to high prevalence of menopause in north america.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the vasomotor symptoms market by therapy type (estrogen, progesterone, combination, OTC hormone, anti-depressants, and others), distribution channel (hospital pharmacy, retail pharmacy, and drug stores), end use (hospitals and clinics, specialty centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Vasomotor Symptoms Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Vasomotor Symptoms Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Vasomotor Symptoms Market by Therapy Type
  • 3.3.1: Estrogen
  • 3.3.2: Progesterone
  • 3.3.3: Combination
  • 3.3.4: OTC Hormone
  • 3.3.5: Anti-Depressants
  • 3.3.6: Others
• 3.4: Global Vasomotor Symptoms Market by Distribution Channel
  • 3.4.1: Hospital Pharmacy
  • 3.4.2: Retail Pharmacy
  • 3.4.3: Drug Stores
• 3.5: Global Vasomotor Symptoms Market by End Use
  • 3.5.1: Hospitals and Clinics
  • 3.5.2: Specialty Centers
  • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Vasomotor Symptoms Market by Region
• 4.2: North American Vasomotor Symptoms Market
  • 4.2.2: North American Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
• 4.3: European Vasomotor Symptoms Market
  • 4.3.1: European Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
  • 4.3.2: European Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
• 4.4: APAC Vasomotor Symptoms Market
  • 4.4.1: APAC Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
  • 4.4.2: APAC Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others
• 4.5: ROW Vasomotor Symptoms Market
  • 4.5.1: ROW Vasomotor Symptoms Market by Therapy Type: Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants, and Others
  • 4.5.2: ROW Vasomotor Symptoms Market by End Use: Hospitals and Clinics, Specialty Centers, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Vasomotor Symptoms Market by Therapy Type
  • 6.1.2: Growth Opportunities for the Global Vasomotor Symptoms Market by Distribution Channel
  • 6.1.3: Growth Opportunities for the Global Vasomotor Symptoms Market by End Use
  • 6.1.4: Growth Opportunities for the Global Vasomotor Symptoms Market by Region
• 6.2: Emerging Trends in the Global Vasomotor Symptoms Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Vasomotor Symptoms Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Vasomotor Symptoms Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Teva Pharmaceuticals
• 7.2: Merck
• 7.3: Mithra Pharmaceuticals
• 7.4: Procter and Gamble
• 7.5: TherapeuticsMD
• 7.6: Emcure Pharmaceuticals
• 7.7: Eli Lily and Company
• 7.8: Novartis
• 7.9: Novo Nordisk
• 7.10: Pfizer